1-chloro-naphthalene-2-sulfonyl chloride | 71862-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-chloro-naphthalene-2-sulfonyl chloride
• 英文别名: 1-Chlor-naphthalin-2-sulfonylchlorid；1-Chlor-naphthalin-sulfonsaeure-(2)-chlorid；1-chloronaphthalen-2-ylsulfonyl chloride；1-Chloronaphthalene-2-sulfonyl chloride
• CAS: 71862-81-2
• 化学式: C₁₀H₆Cl₂O₂S
• 分子量: 261.128
• InChiKey: MFKAFUMBQBYMMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-chloro-naphthalene-2-sulfonyl chloride 在 硝酸 作用下， 生成 1-chloro-7-nitro-naphthalene-2-sulfonyl chloride
  参考文献：
  名称：

  Cleve, 1893, p. 180,185

  摘要：

  DOI：
• 作为产物：
  描述：

  2-萘硫醇 在 氯仿 、 氯 、 溶剂黄146 作用下， 生成 1-chloro-naphthalene-2-sulfonyl chloride
  参考文献：
  名称：

  Zincke; Eismayer, Chemische Berichte, 1918, vol. 51, p. 766

  摘要：

  DOI：

文献信息

• NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1445250A1

  公开（公告）日：2004-08-11

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.

  本发明旨在提供一种新型低分子量胺衍生物，该衍生物被很好地吸收，毒性低，并且具有极高选择性的优异人类β-色氨酸蛋白酶抑制活性，其药学上可接受的盐，以及含有该衍生物作为活性成分的药物。本发明的药物可作为一种预防/治疗剂，用于被认为是由β-色氨酸蛋白酶引起的危机和发展的疾病，例如呼吸道疾病、过敏性疾病、炎症性肠病、皮肤过度增生疾病、血管水肿和类风湿性关节炎。
• Hydantoin derivatives
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US05004751A1

  公开（公告）日：1991-04-02

  The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

  本发明涉及新型咪唑烷酮衍生物，生产所述咪唑烷酮衍生物的方法，含有至少一种所述咪唑烷酮衍生物作为醛糖还原酶抑制剂的药物组合物，以及在合成所述咪唑烷酮衍生物中的新型中间化合物。本发明基于选择一种咪唑烷酮，该咪唑烷酮通过磺酰基与咪唑烷酮骨架的1位上的各种取代基结合。本发明的化合物对醛糖还原酶具有强烈的抑制活性。这些化合物对于治疗和/或预防基于多元醇代谢产物积累的各种糖尿病并发症非常有用。
• SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
  申请人：MCQUIRE Leslie Wighton

  公开号：US20140031399A1

  公开（公告）日：2014-01-30

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了式（I）的化合物：所述化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13异常活性所表征的疾病或疾病。因此，式（I）的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式（I）的药物组合物。
• Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0305947A1

  公开（公告）日：1989-03-08

  The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin 'derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

  本发明涉及新型海因衍生物、生产所述海因'衍生物的工艺、含有至少一种所述海因衍生物作为醛糖还原酶抑制剂的药物组合物以及合成所述海因衍生物的新型中间化合物。 本发明的基础是选择一种通过磺酰基键合在海因骨架 1 位上的各种取代基上的海因。 本发明的化合物对醛糖还原酶具有很强的抑制活性。这些化合物对于治疗和/或预防基于多元醇代谢产物积累的各种糖尿病并发症极为有用。
• Bogdanow; Pawlowskaja, Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1374,1376
  作者：Bogdanow、Pawlowskaja

  DOI：——

  日期：——